Predictive Oncology Inc. (NASDAQ:POAI) held its Q3 2023 Earnings Conference Call on November 14, 2023, at 8:30 AM ET. The call included company participants Glenn Garmont, Raymond Vennare – CEO and Chairman, and Josh Blacher – CFO. The conference was recorded and began with opening remarks by Glenn Garmont, the Investor Relations representative.

Garmont thanked participants for joining the third quarter 2023 earnings call and introduced the upcoming speakers, starting with Chief Executive Officer and Chairman of the Board, Raymond Vennare, who highlighted a research collaboration with Cancer Research Horizons (CRH) that utilized their AI drug discovery platform to evaluate several CRH preclinical glutaminase inhibitor drug compounds. The initial results were provided to CRH and marked a significant milestone for the company in terms of the quick results achieved.

The success has potential financial implications for the company, from development and commercialization milestones to potential sales royalties. Vennare emphasized the significance of the external validation provided by the collaboration, noting its positive impact on business development efforts. The emergence of AI in drug discovery is seen as a transformative development, and Predictive Oncology believes they are at the forefront of this progress.

The company also announced the successful completion of a multiyear retrospective study with UPMC Magee-Women’s Hospital, which built multi-omic machine learning models to predict survival in ovarian cancer. The study, involving one of the largest sets of multi-omic data from 235 ovarian cancer patients, delivered strong predictive models with high levels of accuracy, with plans to present the data at national medical meetings in 2024.

Other significant ongoing projects were also discussed, including a partnership with Cvergenx to develop a genomics-based approach to precision radiation therapy and drug discovery utilizing artificial intelligence, which has resulted in a step one proposal to NASA to search for radioprotective drugs for astronauts during space flight and an SBIR proposal to the NIH. Overall, Predictive Oncology is confident in the potential of AI-driven decision support platforms and innovative developments in drug discovery and cancer research.